A major thrust of clinical research in cognition and aging has been directed towards the identification and potential treatment of the pre-Alzheimer condition known as Mild Cognitive Impairment (MCI). Patients with amnestic MCI appeared to have a high risk of developing dementia, with 12- 15% per year progressing to the point where they meet criteria for Alzheimer's disease, and 50-60% being diagnosed with dementia within five years. Developing effective treatments that will improve symptoms of memory loss and delay or retard the development of dementia in patients who are at high risk is an extremely important public health goal. A number of treatment approaches are being considered or tested including acetylcholinesterase inhibitors, high dose vitamins, hormones, etc. Alterations in brain systems that involve CNS nicotinic receptors appear to be critically important in the development of cognitive impairment resulting in dementia. Loss of nicotinic receptors is one of the most reliable receptor-based findings in Alzheimer's disease and this loss correlates with cognitive impairment. Blockade of nicotinic receptors in normals leads to reversible cognitive impairment in the same domains that are affected in MCI and Alzheimer's disease. Stimulation of nicotinic receptors with nicotine or and/or novel nicotinic agonists reliably improves certain aspects of attentional and memory functioning in both normal individuals, patients with ADHD, schizophrenia, patients with Alzheimer's disease, and in our preliminary studies, MCI patients. Nicotine is arguably the most well studied cognition-enhancing substance known, with hundreds of studies in both tobacco and non-tobacco forms. Furthermore, nicotinic stimulation appears to have significant neuroprotective effects and nicotinic stimulation may have positive influences on APP processing. We propose a pilot 6 month double-blind placebo-controlled trial of transdermal nicotine in 60 patients with amnestic MCI with a 6-month open label extension. Our primary goal is to demonstrate that transdermal nicotine is safe to administer to the non-smoking MCI patients over a one year period. Our secondary goal is to demonstrate cognitive symptom relief/improvement and to gain some preliminary data regarding prevention of progression. Transdermal nicotine has proved to be a extremely safe method of administering nicotine that eliminates the liabilities of tobacco associated nicotine. Patients will be recruited, screened, and treated at 3 major medical centers by investigators who have been leaders in clinical and basic science nicotinic research. Subjects will be tested utilizing sophisticated computerized and non-computerized methodology. Close clinical follow-up will insure patient safety. For reasons outlined above, transdermal nicotine may be an excellent way of improving cognitive performance and delaying progression of MCI. If nicotine proves successful in alleviating cognitive symptoms and in improving global outcomes along with reasonable safety, we will propose a large multicenter clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG022462-02
Application #
6804088
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (M1))
Program Officer
Buckholtz, Neil
Project Start
2003-09-30
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$587,286
Indirect Cost
Name
University of Vermont & St Agric College
Department
Psychiatry
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Newhouse, P; Kellar, K; Aisen, P et al. (2012) Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 78:91-101
Reynolds 3rd, Charles F; Butters, Meryl A; Lopez, Oscar et al. (2011) Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 68:51-60
Newhouse, Paul A; Potter, Alexandra S; Dumas, Julie A et al. (2011) Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol 82:943-51
Brigidi, Bartholomew D; Achenbach, Thomas M; Dumenci, Levent et al. (2010) Broad spectrum assessment of psychopathology and adaptive functioning with the Older Adult Behavior Checklist: a validation and diagnostic discrimination study. Int J Geriatr Psychiatry 25:1177-85
Kaufer, Dan; Gandy, Sam (2009) APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 73:2052-3
Newhouse, Paul A; Potter, Alexandra; Singh, Abhay (2004) Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4:36-46